ProMIS Neurosciences is trading 15% up at $15.78 in pre-market, extending a sharp rebound after recent volatility and profit-taking.
- The move follows prior weakness tied to broader biotech softness and comes as U.S. futures point to a risk-on tone.
- Traders appear to be leaning into a technical recovery rather than reacting to fresh company-specific news or announcements.